By Ben LevisohnUBS analyst Mathhew Roden and team still like biotech stocks, but think it’s time to get more selective, recommending “high quality risk reward names” like Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX), while downgrading Amgen (AMGN) and Regeneron Pharmaceuticals (REGN). They explain why:
Freya Ingrid Morales/Bloomberg News
Although we still think that biotech will continue to outperform the broader markets […]
While the stocks are not cheap, they’re not expensive, he added. What investors are paying for is high quality growth and high quality earnings.Read MoreCramer: Secret pattern to unlocking biotech richesIn fact, he thinks people have underappreciated biotech’s “fantastic” margins, noting that the companies now have 50 to 70 percent operating margins and “tons of real cash flow.””These are real […]
The mixed close Tuesday further clouds the short-term market outlook as it suggests the correction from last week’s highs may not yet be over. A drop in the market tracking ETFs below last Friday’s lows will indicate a decline to more important support. The S&P futures are down in early trading and the heavy selling last week identifies that key […]
By Ben LevisohnLeerink’s Howard Liang and team think 2015 will be another good year for biotech stocks like Gilead Sciences (GILD), Celgene (CELG), Amgen (AMGN ) and Alexion Pharmaceuticals (ALXN). They explain why:
Boston Globe via Getty Images
Biotech fundamentals appear strong, and could attract and broaden investor interest in the sector. Ongoing and upcoming product launches could be among the fastest […]
